Septic cardiomyopathy
Conditions
Interventions
Levosimendan:After completing the examination, the enrolled subjects were treated with levosimendan, with a starting dose of 0.1 µ G/kg/min, without limiting the side effects of speed (such as hypoten
Dobutamine:After completing the examination, the enrolled subjects were treated with dobutamine, with a starting dose of 5 µ G/kg/min, if MAP can be maintained at a normal level (MAP = 65mmHg), mainta
Sponsors
The First Affiliated Hospital of China Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: (1) Comply with the definition standards for sepsis and septic shock in the 2021 International Guidelines for the Management of Sepsis and Septic Shock; Meeting the diagnostic criteria for sepsis cardiomyopathy: excluding organic heart disease; Echocardiography indicates left ventricular ejection fraction = 50%; (2) Age = 18 years old; (3) The patient or their family members sign an informed consent form.
Exclusion criteria
Exclusion criteria: (1) Previously diagnosed as heart failure with reduced or preserved ejection fraction; (2) Have a history of heart valve disease or valve replacement surgery and/or a history of implantable heart device replacement surgery; (3) Patients with underlying heart diseases such as acute coronary syndrome, myocarditis, valvular heart disease, severe arrhythmia, congenital heart disease, dilated cardiomyopathy, etc; (4) Patients with malignant tumors, rheumatic immune system diseases, and severe liver and kidney dysfunction. (5) Individuals who are allergic to levosimendan or dobutamine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left ventricular ejection fraction;Myocardial Blood Flow; | — |
Countries
China
Contacts
Public ContactSun Yitong
The First Affiliated Hospital of China Medical University
Outcome results
None listed